CalciMedica, Inc.
CALC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534133
No open-market purchases or sales by CalciMedica, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $8.39M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:15 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 3, 2026 | Mar 27, 2025 | Jan 22, 2024 | – | Mar 10, 2022 |
| Operating expenses | $23.1M | $24.2M | $38.1M | $36.2M | $35.9M |
| Research and development | $15.2M | $14.5M | $15.9M | $14.1M | $18.9M |
| Selling, general and administrative | $7.89M | $9.73M | $22.2M | $19.1M | $17.0M |
| Operating income | -$23.1M | -$24.2M | -$38.1M | -$36.2M | -$35.9M |
| Income tax | $0 | $0 | $1.00K | – | – |
| Net income | -$29.6M | -$13.7M | -$34.4M | -$35.6M | -$35.8M |
| EPS, basic | $-1.97 | $-1.22 | $-7.66 | $-1.66 | – |
| EPS, diluted | $-1.97 | $-1.22 | $-7.66 | $-1.66 | – |
| Weighted shares, basic | 15.0M | 11.2M | 4.49M | 21.5M | – |
| Weighted shares, diluted | 15.0M | 11.2M | 4.49M | 21.5M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 3, 2026 | Mar 27, 2025 | Jan 22, 2024 | – | Mar 10, 2022 |
| Cash and equivalents | $11.5M | $7.93M | $5.53M | $17.3M | $13.4M |
| Short-term investments | $1.50M | $10.7M | $5.71M | $21.8M | $50.3M |
| Total current assets | $13.5M | $19.7M | $11.6M | $39.7M | $67.1M |
| Property, plant and equipment | $50.0K | $119.0K | $167.0K | – | $1.98M |
| Total assets | $13.6M | $19.8M | $12.2M | $39.7M | $69.1M |
| Accounts payable | $1.16M | $2.00M | $1.42M | $1.72M | $527.0K |
| Total current liabilities | $3.78M | $3.68M | $4.03M | $3.70M | $4.06M |
| Total liabilities | $20.2M | $5.38M | $4.03M | $3.70M | $4.07M |
| Shareholders' equity | -$6.64M | $14.4M | $8.16M | $36.0M | $65.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 3, 2026 | Mar 27, 2025 | Jan 22, 2024 | – | Mar 10, 2022 |
| Operating cash flow | -$21.2M | -$21.1M | -$25.7M | -$22.9M | -$31.5M |
| Capital expenditures | $28.0K | $8.00K | $78.0K | $308.0K | $488.0K |
| Free cash flow | -$21.2M | -$21.2M | -$25.8M | -$23.2M | -$32.0M |
| Depreciation and amortization | – | – | $58.0K | – | – |
| Stock-based compensation | $2.97M | $2.31M | $12.0M | $6.71M | $5.38M |
| Investing cash flow | $9.55M | -$4.42M | $8.88M | $27.0M | $10.8M |
| Financing cash flow | $15.2M | $28.0M | $20.9M | -$139.0K | $695.0K |
| Net change in cash | $3.58M | $2.40M | $4.05M | $3.94M | -$20.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 6.90M | – | SEC |
| Aug 5, 2026 | 34.1M | +144.4% | SEC |
| May 7, 2026 | 15.8M | +13.1% | SEC |
| Feb 26, 2026 | 15.7M | +16.8% | SEC |
| Feb 25, 2026 | 15.7M | +16.8% | SEC |
| Aug 6, 2025 | 14.0M | +30.0% | SEC |
| May 6, 2025 | 14.0M | +30.0% | SEC |
| Mar 21, 2025 | 13.5M | +25.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.